Congressional Letter on use of Bayh-Dole Act to Control Drug Prices
February 22, 2024
A letter signed by 28 members of Congress urging President Biden to reconsider a NIST proposal to use the Bayh-Dole Act to "march in," weaken patents and exert federal control over prescription drug prices.
Download Full Comments Below
Congressional letter to the President on march-in rights
A letter signed by 28 members of Congress to President Biden urging reconsideration of a NIST proposal to use the Bayh-Dole Act to "march in" and control drug prices.
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory-based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative…
A letter signed by 28 members of Congress urging President Biden to reconsider a NIST proposal to use the Bayh-Dole Act to "march in," weaken patents and exert federal control over prescription drug prices.
A letter signed by 28 members of Congress to President Biden urging reconsideration of a NIST proposal to use the Bayh-Dole Act to "march in" and control drug prices.